Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

PHASE3SuspendedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2026

Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
DRUG

ferric citrate

oral tablets

Trial Locations (14)

21287

Johns Hopkins Hospital, Baltimore

33606

University of South Florida, Tampa

35233

University of Alabama at Birmingham (UAB) - Children's of Alabama, Birmingham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

49503

Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids

55455

University of Minnesota, Minneapolis

64108

Children's Mercy Hospital - Kansas City, Kansas City

80045

Children's Hospital Colorado, Aurora

84113

University of Utah, Salt Lake City

85016

Phoenix Childrens Hospital, Phoenix

87110

University of New Mexico, Albuquerque

94158

University of California, San Francisco (UCSF) - Department of Nephrology, San Francisco

94305

Stanford University Medical Center, Stanford

98105

Seattle Children's Hospital, Seattle

Sponsors
All Listed Sponsors
lead

Keryx Biopharmaceuticals

INDUSTRY